Van Der Meeren OHatherill MNduba VWilkinson RJMuyoyeta MVan Brakel EAyles HMHenostroza GThienemann FScriba TJDiacon ABlatner GLDemoitié MATameris MMalahleha MInnes JCHellström EMartinson NSingh TAkite EJKhatoon Azam ABollaerts AGinsberg AMEvans TGGillard PTait DR2025-05-232018-Oct-210.1056/NEJMoa1803484https://pubs.cidrz.org/handle/123456789/10488BACKGROUND: A vaccine to interrupt the transmission of tuberculosis is needed. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 RESULTS: We report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial. A total of 1786 participants received M72/AS01 CONCLUSIONS: M72/AS01